Loading…
enGene Therapeutics Inc. is projected to rise to $2.65 by 2027, a +39% move from its current price of $1.90. ENGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.84 | $1.90 | $1.97 | +0.03% |
| Jul 13 | $1.81 | $1.90 | $2.00 | +0.05% |
| Jul 14 | $1.79 | $1.90 | $2.02 | +0.08% |
| Jul 15 | $1.77 | $1.90 | $2.04 | +0.10% |
| Jul 16 | $1.76 | $1.90 | $2.06 | +0.13% |
| Jul 17 | $1.75 | $1.90 | $2.07 | +0.15% |
| Jul 18 | $1.74 | $1.90 | $2.09 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.74 | $1.90 | $2.09 | +0.18% |
| Week 2 | $1.67 | $1.91 | $2.17 | +0.35% |
| Week 3 | $1.63 | $1.91 | $2.24 | +0.53% |
| Week 4 | $1.59 | $1.91 | $2.30 | +0.71% |
| Week 5 | $1.56 | $1.92 | $2.35 | +0.88% |
| Week 6 | $1.53 | $1.92 | $2.40 | +1.06% |
| Week 7 | $1.51 | $1.92 | $2.45 | +1.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada, operating through its subsidiary enGene, Inc. The company develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2.
The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.
ENGN is the stock name for enGene Therapeutics Inc. The current price is $1.91 and the market capitalization is $127.95M, with a market rank of 4034.
The price outlook is mixed, with a neutral near-term technical picture and longer-term strength suggested by the forecast as bullish from 2027 onward.
The 30-day trading range runs from $1.49 to $2.45, with immediate support at $1.60 and resistance at $1.91.
A major floor 24.2% below — a decisive break under it would weaken the trend.
The nearest floor, 15.8% below — buyers have tended to step in here.
Price is pressing into resistance (1.1% away) — a breakout level to watch.
A major ceiling 412.6% above — clearing it would confirm fresh momentum.
Key ENGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.90 | Sell | $1.88 | Buy |
| MA 10 | $1.83 | Buy | $1.85 | Buy |
| MA 20 | $1.77 | Buy | $1.87 | Buy |
| MA 50 | $2.43 | Sell | $2.80 | Sell |
| MA 100 | $5.22 | Sell | $4.32 | Sell |
| MA 200 | $6.81 | Sell | $5.50 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.63 | Neutral |
| Stoch RSI (14) | 93.41 | Sell |
| CCI (20) | 128.65 | Buy |
| Williams %R (14) | -8.70 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 11.11 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 91.30 | Sell |
| TRIX (15) | -1.51 | Sell |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 69.78 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.93 | Sell |
| ADX (14) | 26.73 | Sell |
| ATR (14) | 0.08 | Info |
Near-term technical picture is neutral, with RSI(14) at 40.
The stock trades below the 50-day simple moving average of $2.88 and well below the 200-day simple moving average of $6.91.
Immediate support sits at $1.60 and resistance at $1.91, framing a 30-day range of $1.49–$2.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.44 | $1.90 | $2.73 | 0% | Neutral | |
| $2.06 | $2.65 | $3.64 | +39% | Bullish | |
| $2.17 | $2.90 | $4.17 | +53% | Bullish | |
| $2.17 | $3.00 | $4.46 | +58% | Bullish | |
| $2.23 | $3.15 | $4.83 | +66% | Bullish | |
| $2.10 | $3.05 | $4.80 | +61% | Bullish | |
| $2.16 | $3.21 | $5.16 | +69% | Bullish | |
| $2.51 | $3.81 | $6.26 | +101% | Bullish | |
| $2.95 | $4.57 | $7.65 | +141% | Bullish | |
| $3.18 | $5.03 | $8.57 | +165% | Bullish | |
| $3.69 | $6.41 | $11.73 | +237% | Bullish | |
| $5.48 | $11.23 | $22.83 | +491% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.44 | $1.90 | $2.33 | +0.00% |
| August 2026 | $1.67 | $1.99 | $2.44 | +4.66% |
| September 2026 | $1.62 | $1.94 | $2.42 | -2.24% |
| October 2026 | $1.62 | $1.96 | $2.46 | +0.72% |
| November 2026 | $1.71 | $2.09 | $2.65 | +6.50% |
| December 2026 | $1.74 | $2.13 | $2.73 | +2.28% |
Click any year to see its month-by-month ENGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ENGN price prediction for 2026 points to an average of $1.90 (low $1.44, high $2.73) — a potential gain of 0% on today's $1.90. A consolidation phase looks the most probable path here.
In 2027, ENGN is projected to trade between $2.06 and $3.64, averaging $2.65 — a potential gain of +39% from today's $1.90. That is up +39% on the projected 2026 average. Momentum favours further upside here.
enGene Therapeutics Inc.'s 2028 outlook centres on $2.90, within a $2.17 to $4.17 range. That is up +10% on the projected 2027 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ENGN could reach as high as $4.46, with a base case around $3.00 and support toward $2.17 — roughly +58% from $1.90. Momentum favours further upside here.
Expect ENGN to range from $2.23 to $4.83 through 2030. The $3.15 average target implies a +66% move from current prices. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ENGN price prediction for 2031 points to an average of $3.05 (low $2.10, high $4.80) — a potential gain of +61% on today's $1.90. Momentum favours further upside here.
In 2032, ENGN is projected to trade between $2.16 and $5.16, averaging $3.21 — a potential gain of +69% from today's $1.90. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
enGene Therapeutics Inc.'s 2033 outlook centres on $3.81, within a $2.51 to $6.26 range. That is up +19% on the projected 2032 average. That marks a +101% change versus current levels. Momentum favours further upside here.
By 2034, ENGN could reach as high as $7.65, with a base case around $4.57 and support toward $2.95 — roughly +141% from $1.90. Buyers look set to stay in control over this stretch.
Expect ENGN to range from $3.18 to $8.57 through 2035. The $5.03 average target implies a +165% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The ENGN price prediction for 2040 points to an average of $6.41 (low $3.69, high $11.73) — a potential gain of +237% on today's $1.90. Buyers look set to stay in control over this stretch.
In 2050, ENGN is projected to trade between $5.48 and $22.83, averaging $11.23 — a potential gain of +491% from today's $1.90. That is up +75% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ENGN today (≈ 526.315789 ENGN) could be worth
$5,908.58
+$4,908.58 (+491%) by 2050 · US Dollar
Based on the average projected ENGN price of $11.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENGNwould be worth at today's price.
$1,000 invested in ENGN on Jul 10, 2025 (≈ 271.739126 ENGN) would be worth
$516.3
-$483.7 (-48.4%) today · 0.52× · US Dollar
Based on a ENGN entry price of $3.68 vs. today's $1.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.78 | $1,067.42 | +6.7% |
| 1 month ago | $1.6 | $1,187.5 | +18.7% |
| 3 months ago | $7.2 | $263.89 | -73.6% |
| 6 months ago | $8.3 | $228.92 | -77.1% |
| 1 year ago | $3.68 | $516.3 | -48.4% |
| All time (4.4y) ago | $9.86 | $192.7 | -80.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENGN forecast.
Our base-case forecast reaches $3.80 around 2033.
Implied market cap at $3.80: $254.56M
The multi-year forecast shows bullish potential beginning in 2027 and extending to 2050.
Key annual averages include 2026 at $1.91, 2027 at $2.73, 2030 at $3.25, 2040 at $6.76 and 2050 at $11.66, with corresponding ROIs of 0%, 42.9%, 70%, 253.7%, and 510.2% respectively.
Max forecast values rise to $2.80 in 2026, $3.81 in 2027, $4.42 in 2028, $4.67 in 2029, $5.09 in 2030, $5.04 in 2031, $5.38 in 2032, $6.72 in 2033, $8.29 in 2034, $9.19 in 2035, $12.80 in 2040, and $24.64 in 2050, with sentiment turning bullish from 2027 onward.
Tap a question to reveal the answer.
Min $2.09, avg $2.73, max $3.81 with bullish sentiment; ROI 42.9%.
Forecasts indicate bullish sentiment from 2027 onward, with rising averages: 2026 avg $1.91 (neutral), 2027 avg $2.73 (bullish), 2028 avg $3.02 (bullish), 2029 avg $3.07 (bullish). ROIs include 42.9% in 2027, 57.9% in 2028, and 60.9% in 2029.
The forecast max by 2050 is $24.64, indicating potential to exceed $10 in the long term.
Current price is $1.91 and market cap is $127.95M.
The 30-day range is $1.49 to $2.45.
enGene Therapeutics Inc. Community Discussion
0Share your enGene Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.